Wang Ma

No. 1 Jianshe East Road
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Acid-enhanced drinkable hydrogel co-delivering riboflavin-loaded nanozymes for orchestrated inflammation-immune modulation and redox homeostasis in colitis therapy.

Acid-enhanced drinkable hydrogel co-delivering riboflavin-loaded nanozymes for orchestrated inflammation-immune modulation and redox homeostasis in colitis therapy.

Journal: Journal of nanobiotechnology

Published: February 23, 2026

Targeting the Gut-Heart Axis: Dextran from Gut-Derived Weissella cibaria Alleviates Doxorubicin-Induced Cardiotoxicity by Attenuating Low-Grade Endotoxemia.

Targeting the Gut-Heart Axis: Dextran from Gut-Derived Weissella cibaria Alleviates Doxorubicin-Induced Cardiotoxicity by Attenuating Low-Grade Endotoxemia.

Journal: Journal of agricultural and food chemistry

Published: December 17, 2025

Association between serum uric acid levels and clinical outcomes of immunotherapy in advanced colorectal cancer patients.

Association between serum uric acid levels and clinical outcomes of immunotherapy in advanced colorectal cancer patients.

Journal: BMC cancer

Published: August 04, 2025

Prognostic Value of Inflammatory and Nutritional Markers in Advanced Esophageal Squamous Cell Carcinoma Treated with Immunotherapy: A Retrospective Cohort Study.

Prognostic Value of Inflammatory and Nutritional Markers in Advanced Esophageal Squamous Cell Carcinoma Treated with Immunotherapy: A Retrospective Cohort Study.

Journal: Journal of inflammation research

Published: June 17, 2025

Dextran from human feces-derived Weissella cibaria facilitates intestinal mucosal barrier function by modulating gut bacteria and propionate levels.

Dextran from human feces-derived Weissella cibaria facilitates intestinal mucosal barrier function by modulating gut bacteria and propionate levels.

Journal: Carbohydrate polymers

Published: September 30, 2024

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial.

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial.

Journal: Cancer pathogenesis and therapy

Published: September 19, 2024

Correction: Atom-precise fluorescent copper cluster for tumor microenvironment targeting and transient chemodynamic cancer therapy.

Correction: Atom-precise fluorescent copper cluster for tumor microenvironment targeting and transient chemodynamic cancer therapy.

Journal: Journal of nanobiotechnology

Published: July 31, 2024

Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Journal: Leukemia & lymphoma

Published: September 21, 2023

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.

Journal: Cancer medicine

Published: August 16, 2023

A novel nomogram based on GD for predicting prognosis in hepatocellular carcinoma.

A novel nomogram based on GD for predicting prognosis in hepatocellular carcinoma.

Journal: Frontiers in oncology

Published: April 24, 2023

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation.

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation.

Journal: Annals of hematology

Published: January 18, 2023

Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse.

Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse.

Journal: Frontiers in oncology

Published: November 14, 2022

Showing 1-12 of 71

Last Updated: 09/26/2026